117 related articles for article (PubMed ID: 1606704)
1. Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma.
Itoh K; Konno T; Sasaki T; Ishiwata S; Ishida N; Misugaki M
Clin Chim Acta; 1992 Mar; 206(3):181-9. PubMed ID: 1606704
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic use of anti-modified nucleoside monoclonal antibody.
Itoh K; Ishiwata S; Ishida N; Mizugaki M
Tohoku J Exp Med; 1992 Oct; 168(2):329-31. PubMed ID: 1306318
[TBL] [Abstract][Full Text] [Related]
3. Creatinine at the evaluation of urinary 1-methyladenosine and pseudouridine excretion.
Honda I; Itoh K; Mizugaki M; Sasaki T
Tohoku J Exp Med; 1999 Jun; 188(2):133-8. PubMed ID: 10526874
[TBL] [Abstract][Full Text] [Related]
4. Detection of elevated amounts of urinary pseudouridine in cancer patients by use of a monoclonal antibody.
Itoh K; Mizugaki M; Ishida N
Clin Chim Acta; 1989 May; 181(3):305-15. PubMed ID: 2758683
[TBL] [Abstract][Full Text] [Related]
5. Urinary excretion patterns of modified nucleosides, pseudouridine and 1-methyladenosine, in healthy individuals.
Itoh K; Aida S; Ishiwata S; Sasaki S; Ishida N; Mizugaki M
Clin Chim Acta; 1993 Aug; 217(2):221-3. PubMed ID: 8261632
[No Abstract] [Full Text] [Related]
6. An immunohistochemical analysis for cancer of the esophagus using monoclonal antibodies specific for modified nucleosides.
Masuda M; Nishihira T; Itoh K; Mizugaki M; Ishida N; Mori S
Cancer; 1993 Dec; 72(12):3571-8. PubMed ID: 8252470
[TBL] [Abstract][Full Text] [Related]
7. Comparison of urinary neopterin and pseudouridine in patients with malignant proliferative diseases.
Motyl T; Traczyk Z; Holska W; Daniewska-Michalska D; Cieśluk S; Kukulska W; Kałuzny Z; Podgurniak M
Eur J Clin Chem Clin Biochem; 1993 Apr; 31(4):205-9. PubMed ID: 8318566
[TBL] [Abstract][Full Text] [Related]
8. [Molecular and immunological approach to hematological disease: detection and analysis of intracellular modified nucleosides by flow cytometry].
Hoshino A; Honda I; Ishimori A; Itoh K; Mizugaki M; Nose M
Rinsho Byori; 1990 Jul; 38(7):756-64. PubMed ID: 2402080
[TBL] [Abstract][Full Text] [Related]
9. Preparation of a monoclonal antibody specific for 1-methyladenosine and its application for the detection of elevated levels of 1-methyladenosine in urines from cancer patients.
Itoh K; Mizugaki M; Ishida N
Jpn J Cancer Res; 1988 Oct; 79(10):1130-8. PubMed ID: 3143701
[TBL] [Abstract][Full Text] [Related]
10. Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma.
Rasmuson T; Björk GR
Acta Oncol; 1995; 34(1):61-7. PubMed ID: 7865238
[TBL] [Abstract][Full Text] [Related]
11. Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas.
Rasmuson T; Björk GR
Cancer Detect Prev; 1983; 6(1-2):293-6. PubMed ID: 6883387
[TBL] [Abstract][Full Text] [Related]
12. [Serum 1-methyladenosine and pseudouridine as tumor markers in tumor-bearing mice].
Ishiwata S; Itoh K; Yamaguchi T; Sasaki S; Ishida N; Mizugaki M
Yakugaku Zasshi; 1995 Jul; 115(7):523-7. PubMed ID: 7562399
[TBL] [Abstract][Full Text] [Related]
13. Relationship between urinary excretion of modified nucleosides and rheumatoid arthritis process.
Tebib JG; Reynaud C; Cedoz JP; Letroublon MC; Niveleau A
Br J Rheumatol; 1997 Sep; 36(9):990-5. PubMed ID: 9376997
[TBL] [Abstract][Full Text] [Related]
14. Urinary modified nucleosides as tumor markers in cancer of the urinary organs or female genital tract.
Koshida K; Harmenberg J; Stendahl U; Wahren B; Borgström E; Helström L; Andersson L
Urol Res; 1985; 13(5):213-8. PubMed ID: 4060364
[TBL] [Abstract][Full Text] [Related]
15. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters.
Masaki Y; Itoh K; Sawaki T; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Wano Y; Hirose Y; Suzuki T; Sugai S; Umehara H
Clin Chim Acta; 2006 Sep; 371(1-2):148-51. PubMed ID: 16643879
[TBL] [Abstract][Full Text] [Related]
16. Liquid chromatographic determination of urinary 5-methyl-2'-deoxycytidine and pseudouridine as potential biological markers for leukaemia.
Zambonin CG; Aresta A; Palmisano F; Specchia G; Liso V
J Pharm Biomed Anal; 1999 Dec; 21(5):1045-51. PubMed ID: 10703973
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of urinary nucleosides by high-performance liquid chromatography.
Liebich HM; Di Stefano C; Wixforth A; Schmid HR
J Chromatogr A; 1997 Feb; 763(1-2):193-7. PubMed ID: 9129323
[TBL] [Abstract][Full Text] [Related]
18. Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA.
Ishiwata S; Itoh K; Yamaguchi T; Ishida N; Mizugaki M
Tohoku J Exp Med; 1995 May; 176(1):61-8. PubMed ID: 7482520
[TBL] [Abstract][Full Text] [Related]
19. Pseudouridine: a prognostic marker in non-Hodgkin's lymphomas.
Rasmuson T; Björk GR
Cancer Detect Prev; 1985; 8(1-2):287-90. PubMed ID: 4064048
[TBL] [Abstract][Full Text] [Related]
20. Urinary excretion of modified nucleosides in chronic myelogenous leukemia.
Heldman DA; Grever MR; Speicher CE; Trewyn RW
J Lab Clin Med; 1983 May; 101(5):783-92. PubMed ID: 6572681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
